BCL2 and B-cell chronic lymphocytic leukemia: Venetoclax, a selective BCL2 inhibitor (BCL2i), combined with a CD20 monoclonal antibody, was shown to have excellent activity in the treatment of both previously untreated and relapsed/refractory CLL/SLL [6,7].